Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
United States
Enrollment target
~350 participants
Started
April 2026
Primary completion
April 2031
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ipsen Clinical Study Enquiries
Ipsen